Search term: media
PHARMAC documents that matched your search:
Agreement offers relief for children with arthritis
(1 page, 36 KB)
Children with arthritis will have access to a new fully-subsidised treatment from 1 February 2004. That’s when PHARMAC will begin subsidising etanercept (Enbrel), a diseasemodifying agent for the treatment of rheumatoid arthritis.
A new treatment for depression will be funded from 1 January 2004 following an agreement between PHARMAC and pharmaceutical company Wyeth (NZ) Ltd.
PHARMAC Board chairman Richard Waddel has welcomed the appointment of Tauranga management consultant Adrienne von Tunzelmann to the Board of the Government drug- funding agency.
Providing new or expanded access to 10 subsidised treatments, including those for chronic myeloid leukaemia, anaemia associated with kidney failure, breast cancer, heavy menstrual bleeding and osteoporosis. Containing community pharmaceutical expenditure growth by successfully negotiating savings worth approximately $50.3 million.
Big jump in statins use but many still not accessing
(2 pages, 38 KB)
More people are getting the benefits of cholesterol-lowering statin drugs but prescribing figures could be higher yet, says PHARMAC Medical Director, Dr Peter Moodie. Figures just released in PHARMAC’s 2003 Annual Review show a massive 65 percent leap in statins prescribing, with about 140,000 people now receiving the medicines.
New Zealanders are taking more medicine than ever before, according to figures just released by drug funding agency PHARMAC. In the year to June 2003, New Zealand patients were written some 22.4 million prescriptions for subsidised medicine (accounting for about two-thirds of all prescribed medicines by value).
PHARMAC predicts continuing drop in HRT prescribing
(1 page, 37 KB)
Even fewer New Zealand women are likely to opt for Hormone Replacement Therapy (HRT) despite the already large drop-off in use, predicts drug funding agency PHARMAC. Figures published in PHARMAC’s Annual Review, released today, show a 38 percent drop in the number of women prescribed HRT during the 2003 financial year.
Wellington-based physician and clinical pharmacologist Professor Carl Burgess has been appointed to chair the Pharmacology and Therapeutics Advisory Committee (PTAC).
PHARMAC will be doing all it can to ensure New Zealanders continue to have access to the heart drug felodipine, following the surprise decision by multinational company AstraZeneca to suddenly cease supplying it to New Zealand.
Everything is in place to ensure a smooth transition to new medicine dispensing rules from 1 October, says PHARMAC Chief Executive Wayne McNee. From 1 October most people will have the added convenience of having to visit the pharmacy less frequently.